TickerGuard
Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Fulgent Genetics Inc (FLGT)

Healthcare Diagnostics & Research
16.60 $
-18.1% vs. previous close
Closing price · As of: 31. Jul 2026
🔔 Watch stock

Stock Watch

Stock Watch will tell you what changes at Fulgent Genetics Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 5 of our scanner strategies — each hit links to the scanner.

Quality & Balance Sheet
Breakout & Setup
Momentum & Trend

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners

Trading Day

Previous Close
20.20$
Open
17.30$
Day High
17.50$
Day Low
16.10$
Volume
1,319,766shares

Key levels of the most recently completed trading day — not a live quote.

52-Week Range

52-Week Low 52-Week High
13.80 $ 30.90 $
03/03/2026 11/25/2025

Current price 16.60 $ — 16% of the range above the low.

Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.

Basics

Market Cap
0.5$B
Shares Outstanding
28Mio.
Float
59.9%
Beta
0.9

Performance

Perf. 1M
12.60%
Perf. 3M
31.70%
Perf. 6M
-24.00%
YTD Performance (%)
-30.80%
52-Week-High Distance
-37.4%
Perf. 1Y
-3.67%
Perf. 3Y
-57.38%
Perf. 5Y
-82.06%
Perf. Since Inception
80.28%

Technical Indicators

MA 38 Days
19.60$
MA 50 Days
19.20$
MA 200 Days
21.40$
RSI (14)
29.4
Volatility 30 Days
66.8%
Volatility 250 Days
66.8%

Calculated from the price history · as of 08/03/2026

Valuation

P/E
Forward P/E
7.7
PEG
1.3
P/B
0.5
P/S
1.4
EV/EBITDA
2.3
Price/FCF

Profitability

Gross Margin
35.6%
EBIT Margin
Net Margin
-26.1%
Return on Equity
-6.9%
Return on Assets
-6.3%

Balance Sheet & Safety

Equity Ratio
Debt/Equity
0.01
fortress balance sheet
Altman Z″
16.22
Piotroski
3 out of 9

Growth

Sales Growth Last Quarter
-3.20%
EPS Growth Last Quarter
Sales Growth (Year)
13.83%
Forward Sales Growth
14.63%
Forward EPS Growth
2.60%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage
4
RS Rating
25
EPS Rating
2
Piotroski
3 out of 9
Fundamental Rating
D (38 out of 100)
fortress balance sheet
Altman Z″
16.22

AI Rating

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Growth Score

6 of 10 Solid growth

Ten checks against the annual reports — each one passed counts a point.

  • Revenue grows by more than 15% a year over three years -19.5% failed
  • More than 10% revenue growth is expected for the coming year 14.6% passed
  • Share count grows by less than 3% a year -0.2% passed
  • Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -24.7% failed
  • Gross margin at 40% or higher and without meaningful erosion 40.6% passed
  • Goodwill from acquisitions does not grow faster than revenue 2.1% passed
  • Net debt below twice EBITDA 328 m net cash passed
  • Operating cash flow covers the profits of the last three years 217 m failed
  • Return on capital at 15% or higher, or up versus two years ago -8.1% failed
  • Insiders hold at least 10% or are net buyers 36.7% passed

A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail

Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.

Analysts & Price Target

Current Price 16.60 $
Price Target (average) 15.00 $

The price target sits 9.6% below the current price.

Consensus
Hold
Analyst Ratings
3
Distribution of Recommendations
Strong Buy 0
Buy 1
Hold 2
Sell 0
Strong Sell 0

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Estimates by Fiscal Year

Estimates by Fiscal Year
Fiscal Year EPS Estimate ($) EPS Range ($) Revenue Estimate ($M) Expected Growth Analysts
12/31/2026 -1.57 -1.59 – -1.55 351 -473.4% 2
12/31/2027 -1.53 -1.91 – -1.15 402 2.6% 2

Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.

Next Reporting Date

7. Aug 2026

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

Revenue & Profit

Cash Flow

Balance Sheet

Margins

Per Share

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)
2024: Q4 · 76.2 $M Q4 2025: Q1 · 73.5 $M Q1 2025: Q2 · 81.8 $M Q2 2025: Q3 · 84.1 $M Q3 2025: Q4 · 83.3 $M Q4 2026: Q1 · 71.1 $M Q1 2026: Q2 · 85.4 $M Q2

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter EPS (Earnings Per Share) EPS YoY (%) Sales ($M) Sales YoY (%) Net Margin (%) OCF ($M) FCF ($M)
2024: Q4 -0.19 76 8.10 -7.70 25 21
2025: Q1 -0.37 74 13.90 -15.70 -4 -9
2025: Q2 -0.61 82 15.20 -23.20 -30 -37
2025: Q3 -0.21 84 17.20 -7.90 11 5
2025: Q4 -0.76 83 9.30 -28.10 -78 -83
2026: Q1 -0.80 71 -3.20 -34.90 7 2
2026: Q2 85 4.40 -34.50 -24 -28
What Do These Terms Mean?
EPS (Earnings Per Share):
Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):
Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:
All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:
What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):
The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):
Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

Annual Figures

Annual Figures
Fiscal Year Revenue ($M) EBIT ($M) Net Income ($M) EPS ($) Operating Cash Flow ($M) Equity ($M) Total Assets ($M)
2016 18 1 -5 -0.30 4 54 58
2017 19 -3 -3 -0.15 1 54 57
2018 21 -5 -4 -0.25 -1 52 55
2019 33 0 0 0.02 6 83 89
2020 422 290 214 8.91 141 569 700
2021 993 104 104 3.37 539 1,159 1,279
2022 619 179 143 4.63 254 1,267 1,386
2023 289 -196 -168 -5.63 27 1,136 1,235
2024 283 -74 -43 -1.41 21 1,133 1,220
2025 323 -91 -61 -1.97 -102 1,112 1,214

Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.

About the Company

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally.

Employees1,315
HeadquartersEl Monte, CA
Address4399 Santa Anita Avenue, 91731 El Monte, United States
Phone626 350 0537
Websitefulgentgenetics.com
IPO Date29. Sep 2016
ISINUS3596641098

Management

Management
Name Title Birth Year
Ming Hsieh Chairman & CEO 1956
Jian Xie COO & President 1966
Paul Kim CPA Chief Financial Officer 1967
Hanlin Gao D.A.B.M.G., FACMG, M.D., Ph.D. Chief Scientific Officer & Lab Director 1967
Natalie Prescott CIPM, CIPP General Counsel & Chief Privacy Officer
Doreen Ng Vice President of Operations & Compliance
Jakub Sram Vice President of Business Development & Sales
Ellen Tsui Vice President of Human Resources
Brandon Perthuis Chief Commercial Officer
Elias Nyankojo Chief Information Security Officer

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
26. Jul 2026 Kim Paul CFO and Treasurer Other 2,747 19.67 54,033
26. Jul 2026 Xie Jian President and COO Other 4,361 19.67 85,781
26. Jul 2026 Gao Hanlin Chief Scientific Officer Other 1,645 19.67 32,357

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.

View all insider transactions →

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?